Kailash C. Chadha, PhD

Editorial Board Member

Department of Molecular and Cellular Biology
Roswell Park Cancer Institute, USA

Contact Kailash C. Chadha, PhD

Department / University Information

Biography

Dr. Kailash Chadha is the Associate Member and Associate Professor of Oncology in the Department of Molecular and Cellular Biology at Roswell Park Cancer Institute, and Department of Medicine, State University of New York at Buffalo, NY, USA. He got his Ph.D. degree in Virology from the University of Guelph, Guelph, Ontario, Canada. After two years of postdoctoral work he joined Roswell Park Cancer Institute in Buffalo, New York as a Cancer Research Scientist in the Department of Medical Viral Oncology. His research interests are in the area of cell and molecular biology of Herpes viruses, interferons and prostate cancer. He has published well over 125 publications, written several book chapters, edited a book on Interferon and currently holds four U.S. patents. He is currently on the editorial board of several journals. He is member of several professional organizations including New York Academy of Sciences; American Association for the Advancement of Science; Society for Experimental Biology & Medicine; American Association for Cancer Research; International Society for Interferon & Cytokine research and The Society of Basic Urologic Research etc.

Research Interest

The physiological role of PSA in prostate tissue microenvironment, in prostate tumor growth and progression, and in prostate cancer metastasis is not known. Attenuation of PSA levels with age, disease progression, or during androgen deprivation therapy, however, removes this important regulator of angiogenesis, and by extension results in tumor progression. Re-introduction of human PSA into the prostate tissue microenvironment may suppress tumor angiogenesis through either the inhibition of expression of pro-angiogenic genes or induction of expression of anti-angiogenic genes, or via inhibition of signaling mechanisms associated with angiogenesis that are independent of gene transcription. Validation of an anti-angiogenic effect of PSA on the human tissue vasculature in a pre-clinical model of primary xenografts of human prostate and prostate cancer tissue will provide compelling evidence that PSA has therapeutic potential against prostate cancer.

Related Publications

Share This Page